ANRO

Alto Neuroscience Inc. (ANRO) | Rumor.io

Alto Neuroscience

ANRO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,702

Bullish sentiment (50-day avg)100%

Price to earnings ratio-12.2

Market capitalization1B

Earnings per share-2.32

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-63.2M

Social

What share of all stock conversation is about ANRO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Apr 2

Alto Neuroscience's ($ANRO) Phase 2 proof-of-concept study of ALTO-101 for schizophrenia failed to achieve statistical significance on primary endpoints.
The company will discontinue independent advancement of the program and is seeking a partner to help further develop an extended-release oral formulation of ALTO-101.
$ANRO's stock price dropped 10.3% after the disappointing study results, but analysts see the dip as an attractive entry point.

Generated by AI

Sentiment

Of the messages about ANRO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	94.78% +10.07
Bearish	—	0%	0% 0	5.22% -10.07

Bullish· Oct 20

Alto Neuroscience ($ANRO) raised $50M after receiving positive FDA feedback, accelerating its lead compound ALTO-207 in treating TRD.
The company's de-risked drug, ALTO-207, shows potential paradigm-shifting efficacy in TRD, and its approval as a take-home treatment is possible if replicated data is confirmed.
Baird upgraded its stance on Alto Neuroscience to Outperform with a target price of $16, following a significant price increase of over 90%.

Bearish· Oct 3

The company is facing a class action lawsuit for alleged fraud, including insider trading.
Short sellers are actively working to keep the stock price down, despite facing challenges.
The stock price may retrace significantly, potentially falling to $4 or even $15.

Generated by AI

Topics

Of the messages about ANRO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	100%	19.79%
Announcements	—	—	0%	54.64%
Analysts	—	—	0%	12.93%
Controversies	—	—	0%	2%
Earnings	—	—	0%	0.5%
Macro	—	—	0%	10.14%

Announcements· Oct 3

Alto Neuroscience's (ANRO) ALTO-101 has received FDA Fast Track designation for the treatment of cognitive impairment associated with schizophrenia.
The designation is a significant milestone for the ALTO-101 program, with early data showing significant and clinically relevant effects on electroencephalogram measures and cognitive performance in healthy subjects.
Enrollment is ongoing in a Phase 2 proof-of-concept study in patients with cognitive impairment associated with schizophrenia, with potential eligibility for accelerated approval or priority review if criteria are met.

Technical Analysis· Oct 3

$ANRO is expected to break out above $8.17, potentially reaching a target of $10.06.
The stock is in a strong uptrend, with a 92.5% confidence level, and has a bullish MACD and RSI.
A falling wedge pattern is likely to break up, with the stock potentially reaching $15.04.

Generated by AI

Community

Of the messages about ANRO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	73.63%	27.34%
Newcomers	0%	0%	26.37%	72.66%

Oct 24

New investors are excited about Alto Neuroscience's stock placement, which they believe will help the company accelerate plans for its ALTO-207 treatment for depression.
The newcomers are focusing on the potential of ALTO-207 to treat depression, a condition that affects millions of people worldwide, and its possible impact on the mental health sector.
These new investors are also paying attention to analyst support for Alto Neuroscience, which they see as a positive indicator for the company's stock performance and future growth prospects.

Generated by AI

MOUNTAIN VIEW, Calif., September 09, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:

21d agoYahoo Finance

Alto Neuroscience promotes Nick Smith to president and CFO

1mo agoInvesting.com

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

MOUNTAIN VIEW, Calif., August 27, 2026--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026.

1mo agoYahoo Finance

Alto Neuroscience stock hits all-time high at 35.42 USD

1mo agoInvesting.com

Also Discussed

Investors talking about ANRO also mention

#	Name	Attention
1	Neumora Therapeutics, Inc. Common StockNMRA	0%0
2	Bright Minds Biosciences Inc.DRUG	0%new
3	Praxis Precision Medicines, Inc.PRAX	0%0
4	Spruce Biosciences, Inc.SPRB	0%0
5	Cingulate Inc.CING	0%new
6	Treace Medical Concepts Inc.TMCI	0%0
7	Firefly Neuroscience IncAIFF	0%-0.01
8	Infobird Co. Ltd.IFBD	0%0
9	Opus Genetics, Inc. Common StockIRD	0%0
10	Allogene Therapeutics IncALLO	0%new

Alto Neuroscience Inc.

Healthcare
Biotechnology

Alto Neuroscience Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for neuropsychiatric disorders. Alto Neuroscience applies its Precision Psychiatry Platform to analyze brain biomarkers, EEG activity, neurocognitive assessments, wearable data, and other patient-specific measures to help match therapies with the people most likely to benefit. Its current pipeline includes drug candidates targeting bipolar depression, major depressive disorder, treatment-resistant depression, schizophrenia, and related cognitive and mood disorders. The company is centered on personalized psychiatry, using biology-driven research to support the development of novel psychiatric treatments. Alto Neuroscience is headquartered in Mountain View, California, and its work today is concentrated on advancing clinical-stage programs for mental health conditions through biomarker-guided drug development.

Website

Location

650 Castro Street

Mountain View, CA, 94041

United States

Social

What share of all stock conversation is about ANRO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Apr 2

Alto Neuroscience's ($ANRO) Phase 2 proof-of-concept study of ALTO-101 for schizophrenia failed to achieve statistical significance on primary endpoints.
The company will discontinue independent advancement of the program and is seeking a partner to help further develop an extended-release oral formulation of ALTO-101.
$ANRO's stock price dropped 10.3% after the disappointing study results, but analysts see the dip as an attractive entry point.

Generated by AI

Sentiment

Of the messages about ANRO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	94.78% +10.07
Bearish	—	0%	0% 0	5.22% -10.07

Bullish· Oct 20

Alto Neuroscience ($ANRO) raised $50M after receiving positive FDA feedback, accelerating its lead compound ALTO-207 in treating TRD.
The company's de-risked drug, ALTO-207, shows potential paradigm-shifting efficacy in TRD, and its approval as a take-home treatment is possible if replicated data is confirmed.
Baird upgraded its stance on Alto Neuroscience to Outperform with a target price of $16, following a significant price increase of over 90%.

Bearish· Oct 3

The company is facing a class action lawsuit for alleged fraud, including insider trading.
Short sellers are actively working to keep the stock price down, despite facing challenges.
The stock price may retrace significantly, potentially falling to $4 or even $15.

Generated by AI

Topics

Of the messages about ANRO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	100%	19.79%
Announcements	—	—	0%	54.64%
Analysts	—	—	0%	12.93%
Controversies	—	—	0%	2%
Earnings	—	—	0%	0.5%
Macro	—	—	0%	10.14%

Announcements· Oct 3

Alto Neuroscience's (ANRO) ALTO-101 has received FDA Fast Track designation for the treatment of cognitive impairment associated with schizophrenia.
The designation is a significant milestone for the ALTO-101 program, with early data showing significant and clinically relevant effects on electroencephalogram measures and cognitive performance in healthy subjects.
Enrollment is ongoing in a Phase 2 proof-of-concept study in patients with cognitive impairment associated with schizophrenia, with potential eligibility for accelerated approval or priority review if criteria are met.

Technical Analysis· Oct 3

$ANRO is expected to break out above $8.17, potentially reaching a target of $10.06.
The stock is in a strong uptrend, with a 92.5% confidence level, and has a bullish MACD and RSI.
A falling wedge pattern is likely to break up, with the stock potentially reaching $15.04.

Generated by AI

Community

Of the messages about ANRO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	73.63%	27.34%
Newcomers	0%	0%	26.37%	72.66%

Oct 24

New investors are excited about Alto Neuroscience's stock placement, which they believe will help the company accelerate plans for its ALTO-207 treatment for depression.
The newcomers are focusing on the potential of ALTO-207 to treat depression, a condition that affects millions of people worldwide, and its possible impact on the mental health sector.
These new investors are also paying attention to analyst support for Alto Neuroscience, which they see as a positive indicator for the company's stock performance and future growth prospects.

Generated by AI

Alto Neuroscience

Social

Apr 2

Sentiment

Bullish· Oct 20

Bearish· Oct 3

Topics

Announcements· Oct 3

Technical Analysis· Oct 3

Community

Oct 24

News

Alto Neuroscience at TD Cowen summit: pramipexole combo takes center stage

Alto Neuroscience at H.C. Wainwright: pipeline breadth gains focus

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience promotes Nick Smith to president and CFO

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Alto Neuroscience stock hits all-time high at 35.42 USD

Also Discussed

Alto Neuroscience Inc.

Company Information

Location

News

Alto Neuroscience at TD Cowen summit: pramipexole combo takes center stage

Alto Neuroscience at H.C. Wainwright: pipeline breadth gains focus

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience promotes Nick Smith to president and CFO

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Alto Neuroscience stock hits all-time high at 35.42 USD

Also Discussed

Social

Apr 2

Sentiment

Bullish· Oct 20

Bearish· Oct 3

Topics

Announcements· Oct 3

Technical Analysis· Oct 3

Community

Oct 24